Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system

Journal of Gene Medicine

Volumn 5, Issue 3, 2003, Pages 190-200

  Block, Andreas ^a   Puls, Florian ^a   Müller, Jürgen ^a   Milasinovic, Dragan ^a   Igelmann, Dana ^a   Schäfer, Peter ^a   Kupfermann, Nikolai ^a   Schmoldt, Achim ^a   Ameis, Detlev ^a   Greten, Heiner ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adenovirus; Doxycycline; Interleukin 12; Luciferase; Tet; tTA transactivator

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; DOXYCYCLINE; GAMMA INTERFERON; GLYCOPROTEIN E1; INTERLEUKIN 12; LUCIFERASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETRACYCLINE; TRANSACTIVATOR PROTEIN; ANTIINFECTIVE AGENT; REPRESSOR PROTEIN; TETRACYCLINE RESISTANCE ENCODING TRANSPOSON REPRESSOR PROTEIN; TETRACYCLINE RESISTANCE-ENCODING TRANSPOSON REPRESSOR PROTEIN;

ADULT; ARTICLE; AUTOREGULATION; BLOOD DONOR; CANCER IMMUNOTHERAPY; CELL LINE; CELL SECRETION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SAFETY; FEMALE; GENE CONSTRUCT; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; GENE STRUCTURE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTOXICITY; INTERMETHOD COMPARISON; LETHALITY; MALE; MOLECULAR CLONING; NONHUMAN; OPERATOR GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REPORTER GENE; SPLEEN CELL; TRANSGENE; TUMOR IMMUNOLOGY; VIRUS INFECTION; VIRUS RECOMBINANT; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; HELA CELL; MOUSE;

ADENOVIRIDAE; ANIMALS; ANTI-BACTERIAL AGENTS; DOXYCYCLINE; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HELA CELLS; HUMANS; INTERLEUKIN-12; MICE; REPRESSOR PROTEINS;

EID: 0142166340     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.334     Document Type: Article

References (52)

1. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-5551.
2. Gossen M, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
3. Harding TC, et al. Tetracycline-regulated transgene expression in hippocampal neurones following transfection with adenoviral vectors. J Neurochem 1997; 69: 2620-2623.
4. Harding TC, et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol 1998; 16: 553-555.
5. Rubinchik S, et al. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000; 7: 875-885.
6. Strathdee CA, McLeod MR, Hall JR. Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene 1999; 229: 21-29.
7. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995; 2: 96-106.
8. Caruso M, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996; 93: 11302-11306.
9. Sun Y, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998; 5: 481-490.
10. Kang WK, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12: 671-684.
11. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997; 15: 35-40.
12. Lode HN, et al. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci U S A 1998; 95: 2475-2480.
13. Ling P, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995; 154: 116-127.
14. Gillessen S, et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 1995; 25: 200-206.
15. Mattner F, et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993; 23: 2202-2208.
16. Leonard JP, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541-2548.
17. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999; 27: 58-63.
18. Cotten M, et al. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther 1994; 1: 239-246.
19. Tong X, et al. The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter. Anticancer Res 1998; 18: 719-725.
20. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
21. Graham FL, Eb AJvd. Transformation of rat cells by DNA of human adenovirus 5. Virology 1973; 54: 536-539.
22. Nesbitt SA, Horton MA. A nonradioactive biochemical characterization of membrane proteins using enhanced chemiluminescence. Anal Biochem 1992; 206: 267-272.
23. Sheridan ME, Clarke GS. Improved high-performance liquid chromatographic determination of doxycycline in serum and urine using solid-phase extraction columns. J Chromatogr 1988; 434: 253-258.
24. De Wasch K, et al. Detection of residues of tetracycline antibiotics in pork and chicken meat: correlation between results of screening and confirmatory tests. Analyst 1998; 123 2737-2741.
25. Block A, et al. Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase. Cancer Gene Ther 2000; 7: 438-445.
26. Pellett PE, McKnight JL, Jenkins FJ, Roizman B. Nucleotide sequence and predicted amino acid sequence of a protein encoded in a small herpes simplex virus DNA fragment capable of trans-inducing alpha genes. Proc Natl Acad Sci U S A 1985; 82: 5870-5874.
27. June CH, Ledbetter JA, Lindsten T, Thompson CB. Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J Immunol 1989; 143: 153-161.
28. Oka H, et al. Mass spectrometric analysis of tetracycline antibiotics in foods. J Chromatogr A 1998; 812: 309-319.
29. Colombo MP, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996; 56: 2531-2534.
30. Martinotti A, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995; 25: 137-146.
31. Mazzolini G, et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther 2001; 8: 259-267.
32. Molin M, et al. Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J Virol 1998; 72: 8358-8361.
33. Rubinchik S, et al. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters. Gene Ther 2001; 8: 247-253.
34. Nakagawa S, Massie B, Hawley RG. Tetracycline-regulatable adenovirus vectors: pharmacologic properties and clinical potential. Eur J Pharm Sci 2001; 13: 53-60.
35. Corti O, et al. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1999; 96: 12 120-12 125.
36. Schultze N, et al. Efficient control of gene expression by single step integration of the tetracycline system in transgenic mice. Nat Biotechnol 1996; 14: 499-503.
37. Shockett P, Difilippantonio M, Hellman N, Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A 1995; 92: 6522-6526.
38. Massie B, et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 1998; 72: 2289-2296.
39. Shockett P, Schatz D. Switching on gene expression. Nat Biotechnol 1997; 15: 219-221.
40. Putzer BM, et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 1997; 94 10 889-10 894.
41. Wen XY, et al. Tricistronic vital vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001; 8: 361-370.
42. Murphy FJ, Hayes MP, Burd PR. Disparate intracellular processing of human IL-12 preprotein subunits: atypical processing of the P35 signal peptide. J Immunol 2000; 164: 839-847.
43. Carra G, Gerosa F, Trinchieri G. Biosynthesis and posttranslational regulation of human IL-12. J Immunol 2000; 164 4752-4761.
44. MacGregor GR, Caskey CT. Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res 1989; 17: 2365.
45. Pederson LC, et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4325-4332.
46. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-810.
47. Seguret-Mace S, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996; 94: 2177-2184.
48. DeYoung MB, et al. Optimizing vascular gene transfer of plasminogen activator inhibitor 1. Hum Gene Ther 1999; 10: 1469-1478.
49. Ritter T, et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 2000; 12: 1163-1170.
50. Sadowski I, Ma J, Triezenberg S, Ptashne M. GAL4-VP16 is an unusually potent transcriptional activator. Nature 1988; 335: 563-564.
51. Triezenberg SJ, LaMarco KL, McKnight SL. Evidence of DNA: protein interactions that mediate HSV-1 immediate early gene activation by VP16. Genes Dev 1988; 2: 730-742.
52. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78 1653-1661.